Strategic Acquisition As a part of WuXi AppTec, HD Biosciences benefits from a robust global platform, enhancing its capacity to serve international pharmaceutical clients and providing opportunities to expand its service offerings in preclinical drug discovery.

Growing Market Footprint With an estimated revenue between 25 million and 50 million USD and operational facilities in Shanghai, San Diego, and Cranbury, HD Biosciences is well-positioned to attract pharmaceutical companies seeking comprehensive preclinical CRO services across key biotech hubs.

Innovation-Driven Services Specializing in target validation, pharmacology, and lead discovery, HD Biosciences aligns with the industry trend toward innovative drug development, offering advanced research capabilities that can meet the evolving needs of biotech and pharma R&D teams.

High-Quality Expertise Known for consistent, high-quality deliverables and scientific expertise, HD Biosciences appeals to clients requiring reliable preclinical testing and research, making it a potential partner for organizations seeking trusted CRO collaboration.

Technology Utilization Utilizing technology tools like ASP.NET, Windows Server, and analytics platforms, HD Biosciences demonstrates its capacity for integrating advanced IT infrastructure—an essential aspect for clients looking for state-of-the-art research support and data management solutions.